BioArctic AB (publ) (BIOA-B) - Total Assets
Based on the latest financial reports, BioArctic AB (publ) (BIOA-B) holds total assets worth Skr2.60 Billion SEK (≈ $279.92 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore BioArctic AB (publ) debt service capacity to assess how comfortably operating cash covers total debt obligations.
BioArctic AB (publ) - Total Assets Trend (2015–2024)
This chart illustrates how BioArctic AB (publ)'s total assets have evolved over time, based on quarterly financial data. See BIOA-B total equity for net asset value and shareholders' equity analysis.
BioArctic AB (publ) - Asset Composition Analysis
Current Asset Composition (December 2024)
BioArctic AB (publ)'s total assets of Skr2.60 Billion consist of 90.9% current assets and 9.1% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr512.93 Million | 46.1% |
| Accounts Receivable | Skr213.55 Million | 19.2% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr96.62 Million | 8.7% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how BioArctic AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is BioArctic AB (publ) worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioArctic AB (publ)'s current assets represent 90.9% of total assets in 2024, an increase from 90.3% in 2015.
- Cash Position: Cash and equivalents constituted 46.1% of total assets in 2024, down from 86.8% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is cash and equivalents at 46.1% of total assets.
BioArctic AB (publ) Competitors by Total Assets
Key competitors of BioArctic AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Akero Therapeutics Inc
NASDAQ:AKRO
|
USA | $1.01 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr16.46 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
BioArctic AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.18 | 8.35 | 9.27 |
| Quick Ratio | 4.18 | 8.35 | 9.27 |
| Cash Ratio | 1.84 | 5.10 | 0.00 |
| Working Capital | Skr1.91 Billion | Skr871.21 Million | Skr899.64 Million |
BioArctic AB (publ) - Advanced Valuation Insights
This section examines the relationship between BioArctic AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 14.98 |
| Latest Market Cap to Assets Ratio | 2.34 |
| Asset Growth Rate (YoY) | -6.3% |
| Total Assets | Skr1.11 Billion |
| Market Capitalization | $2.60 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values BioArctic AB (publ)'s assets at a significant premium (2.34x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: BioArctic AB (publ)'s assets decreased by 6.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for BioArctic AB (publ) (2015–2024)
The table below shows the annual total assets of BioArctic AB (publ) from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr1.11 Billion ≈ $119.63 Million |
-6.27% |
| 2023-12-31 | Skr1.19 Billion ≈ $127.64 Million |
+38.19% |
| 2022-12-31 | Skr858.31 Million ≈ $92.37 Million |
-4.39% |
| 2021-12-31 | Skr897.73 Million ≈ $96.61 Million |
-14.53% |
| 2020-12-31 | Skr1.05 Billion ≈ $113.03 Million |
-11.24% |
| 2019-12-31 | Skr1.18 Billion ≈ $127.35 Million |
-15.05% |
| 2018-12-31 | Skr1.39 Billion ≈ $149.91 Million |
+22.14% |
| 2017-12-31 | Skr1.14 Billion ≈ $122.73 Million |
+61.09% |
| 2016-12-31 | Skr707.98 Million ≈ $76.19 Million |
+439.98% |
| 2015-12-31 | Skr131.11 Million ≈ $14.11 Million |
-- |
About BioArctic AB (publ)
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, … Read more